LIPA and Niemann-Pick disease type C: The properties of L1 and L2 (originally reported as compounds 13 and 12, respectively) and their ability to pharmacologically inhibit LAL were described more than 10 years ago during screening for compounds as therapeutic agents for Niemann-Pick type C disease [30,31].